Locations:
Search IconSearch
January 3, 2017/Cancer/News & Insight

Q. Should We Treat All Breast Cancer Aggressively, Just to be Safe?

650×450-grobmeyer

Q. Should we treat all breast cancer aggressively, just to be safe?

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A. All patients don’t need all treatments. As our knowledge and understanding of outcomes has improved, we can safely personalize care. Using evidence-based management practices, we often are able to provide the best results with less treatment and minimal side effects.

Studies have shown that some patients over age 65 with early-stage breast cancer may be safely managed with surgery alone and may not need chemotherapy or radiation. In fact, radiation has not been shown to improve long-term survival in these patients

Similarly, chemotherapy is no longer prescribed for certain stages and types of breast cancer. We use molecular tests to determine which patients will and won’t benefit from chemotherapy.

For some patients when radiation is warranted, a single dose of intraoperative radiation can lower recurrence risk in a cost-effective way without causing side effects.

Because prognostic information based on molecular type allows us to personalize care, we engage patients in discussions of benefit and risk. They need to know that aggressive treatment may not always mean better outcomes.

Stephen Grobmyer, MD

Advertisement

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023/Cancer/News & Insight
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023/Cancer/News & Insight
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023/Cancer/News & Insight
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023/Cancer/News & Insight
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023/Cancer/News & Insight
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023/Cancer/News & Insight
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023/Cancer/News & Insight
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

Ad